The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives

Clin J Oncol Nurs. 2004 Jun;8(3):307-8, 310. doi: 10.1188/04.CJON.307-308.

Abstract

First-generation serotonin receptor antagonists greatly improved the control of chemotherapy-induced nausea and vomiting (CINV) during the 1990s. A new class of agents, neurokinin-1 receptor antagonists, was introduced in March 2003 and produced even greater control of CINV when used in combination with a serotonin receptor antagonist and a corticosteroid. In July 2003, palonosetron, a new second-generation serotonin receptor antagonist that has greater potency and a longer half-life than first-generation serotonin receptor antagonists, was introduced. This clinical update reviews studies that were conducted to evaluate these new agents.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antiemetics / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Isoquinolines / administration & dosage*
  • Isoquinolines / adverse effects
  • Male
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Palonosetron
  • Prognosis
  • Quinuclidines / administration & dosage*
  • Quinuclidines / adverse effects
  • Serotonin 5-HT3 Receptor Antagonists*
  • Treatment Outcome
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Isoquinolines
  • Quinuclidines
  • Serotonin 5-HT3 Receptor Antagonists
  • Palonosetron